聚焦伯恩斯坦_中国医药及生物科技:投资者营销会议上的主要问题解答。BeOne: With our recent BeOne upgrade, most questions are on potential upsides from the$41 Bn market cap today. Investors are generally more bullish on Brukinsa and many find our $5Bn peak sales conservative. 1) Brukinsa IRA price cut exemption and upside.
聚焦伯恩斯坦_中国医药及生物科技:投资者营销会议上的主要问题解答。BeOne: With our recent BeOne upgrade, most questions are on potential upsides from the$41 Bn market cap today. Investors are generally more bullish on Brukinsa and many find our $5Bn peak sales conservative. 1) Brukinsa IRA price cut exemption and upside.
聚焦伯恩斯坦_中国医药及生物科技:投资者营销会议上的主要问题解答。BeOne: With our recent BeOne upgrade, most questions are on potential upsides from the$41 Bn market cap today. Investors are generally more bullish on Brukinsa and many find our $5Bn peak sales conservative. 1) Brukinsa IRA price cut exemption and upside.
覆盖 2026 年,全文共 23 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了医药、营销、伯恩斯坦_中国医药及生物科技等议题。